Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

1.060 +0.020 (+1.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Results Of Human Clinical Study Showing Effective, Safe BP Reduction
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study HYPER-H21-2, which features LEXX’s patented... 
Via Benzinga
Why Lexaria Bioscience Shares Are Trading Higher Today
Lexaria Bioscience Corp (NASDAQ: LEXX) is trading higher Tuesday after the company announced initial results from its human clinical study of DehydraTECH, saying the study... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Pliant Therapeutics (NASDAQ:PLRX) shares rose 25.62% to $24.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $872.2... 
Via Benzinga
Lexaria Bioscience's Formulated Cannabidiol Lowers Blood Pressure In Hypertension Patients
Lexaria Bioscience Corp (NASDAQ: LEXX) has announced initial results from human clinical study HYPER-H21-2 evaluating DehydraTECH-processed cannabidiol (CBD) for potential... 
Via Benzinga
Lexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period
Human Clinical Study HYPER-H21-2 evidences up to a remarkable 23% decrease in blood pressure with patented DehydraTECH-CBD relative to placebo KELOWNA, BC / ACCESSWIRE / September 7, 2021 / Lexaria... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Proprietary Technology Elevating Quantity of Drugs Delivered Across Blood-Brain Barrier by 1,900%
Via CannabisNewsWire
Topics Animal Testing Intellectual Property
Exposures Animal Testing COVID-19 Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Targets Burgeoning Hypertension, Antiviral Therapeutics Markets With Drug Delivery Technology
Lexaria has progressed significantly in evidencing that its patented DehydraTECH(TM) drug delivery technology can sufficiently improve the usable fraction of known antiviral... 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology Is ‘Outrageously Fast’ in Oral to Bloodstream Delivery
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in PCG Report Noting Company Could Deliver for Investors
Via CannabisNewsWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH Provides Potential for Significant Cost Savings to Health Care System
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Well Positioned to Advance Business, Further Execute on Drug-Delivery Goals
Via CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Hails Successful Testing for Effective Transformation of Antivirals for Greater Bioavailability
Via CannabisNewsWire
Lexaria's R&D Program Reveals 5 Exciting Results Within 2 Months
Image by Lucas Vasques on Unsplash Biotech company Lexaria Bioscience Corp. (NASDAQ: LEXX) has been making news for DehydraTECH™ — its proprietary disruptive and cost-... 
Via Benzinga
Lexaria's DehydraTECH-CBD Lowers Blood Pressure
Human Clinical Study HYPER-H21-1 evidences a rapid and sustained drop in blood pressure with DehydraTECH-CBD and excellent tolerability KELOWNA, BC / ACCESSWIRE / July 29, 2021 / Lexaria Bioscience... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reaches Milestone in Human Clinical Study, Notes Growing Availability of DehydraTECH-Enabled Products
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
DehydraTECH-Enabled Consumer Products Now Available in Over 7,000 Stores
Lexaria's technology empowers brands nationwide in stores including Albertsons, Hudson News, and many more KELOWNA, BC / ACCESSWIRE / July 28, 2021 / Lexaria Bioscience Corp.... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property Supply Chain
Exposures Intellectual Property Supply Chain
Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes VIRAL-A20-3 Pharmacokinetic Study on DehydraTECH(TM) Enabled Colchicine
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Eyegate Pharmaceuticals (NASDAQ:EYEG) shares increased by 131.41% to $7.22 during Tuesday's pre-market session. The company's market cap stands at $51.2... 
Via Benzinga
Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2
Additionally, second patent award received in Japan KELOWNA, BC / ACCESSWIRE / July 27, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Receives US$3,817,643 From Warrant Exercises
KELOWNA, BC / ACCESSWIRE / July 26, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Test Results Boost Lexaria Bioscience Corp. (NASDAQ: LEXX) Potential in Enhancing Antiviral Drugs
Via CannabisNewsWire
Exposures COVID-19
61 Biggest Movers From Yesterday
Gainers ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) shares jumped 138.2% to close at $13.22 on Thursday after the company announced new results from its TATX-03 PolyTope Therapy... 
Via Benzinga
38 Stocks Moving In Thursday's Mid-Day Session
Gainers ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) shares climbed 129.7% to $12.75 after the company announced new results from its TATX-03 PolyTope Therapy, demonstrating... 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Results of Antiviral Drug Studies, Strategy Moving Forward
Via CannabisNewsWire
Topics Animal Testing
Exposures Animal Testing
Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy
All objectives evaluating DehydraTECH™ drug delivery platform successfully achieved KELOWNA, BC / ACCESSWIRE / July 22, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Animal Testing Death Intellectual Property
Exposures Animal Testing COVID-19 Death
21 Stocks Moving in Thursday's Pre-Market Session
Gainers PainReform Ltd (NASDAQ: PRFX) shares rose 123% to $7.00 in pre-market trading. Second Sight Medical Products Inc (NASDAQ: EYES) shares rose 29% to $5.57 in pre-market... 
Via Benzinga
61 Biggest Movers From Yesterday
Gainers Chembio Diagnostics, Inc. (NASDAQ: CEMI) shares surged 159.2% to close at $5.34 on Wednesday after the company received a $28.3 million purchase order from Brazil's... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Second Sight Medical (NASDAQ:EYES 
Via Benzinga
Mid-Afternoon Market Update: Dow Jumps 250 Points; Sleep Number Shares Slide After Q2 Results
Toward the end of trading Wednesday, the Dow traded up 0.73% to 34,765.42 while the NASDAQ rose 0.66% to 14,594.38. The S&P also rose, gaining 0.69% to 4,352.90. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Chembio Diagnostics (NASDAQ:CEMI) stock rose 189.72% to $5.97 during Wednesday's regular session. Trading volume for Chembio Diagnostics's stock is 265.3... 
Via Benzinga
< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback